Literature DB >> 25620839

Synthesis of pyridine derivatives as potential antagonists of chemokine receptor type 4.

Suazette Reid Mooring1, Theresa Gaines1, Zhongxing Liang2, Hyunsuk Shim2.   

Abstract

A series of pyridine derivatives were synthesized as potential inhibitors of chemokine receptor type 4. This chemokine receptor has been linked to various disease pathways including HIV-1 proliferation, autoimmune disorders, inflammatory diseases, and cancer metastasis. The compounds were tested for activity using an affinity binding assay and an assay that tests the ability to inhibit cell invasion. Two hit compounds (2b and 2j) have been identified for further evaluation that inhibit cell invasion by at least 50% and have an effective concentration of less than 100 nM in the binding affinity assay. The structures of the synthesized compounds were confirmed by spectral data.

Entities:  

Keywords:  CXC chemokine receptor type 4 (CXCR4); anti-cancer; anti-inflammatory; pyridine derivatives

Year:  2014        PMID: 25620839      PMCID: PMC4300533          DOI: 10.1515/hc-2014-0041

Source DB:  PubMed          Journal:  Heterocycl Comm        ISSN: 0793-0283            Impact factor:   1.120


  23 in total

Review 1.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 2.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

Review 3.  The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.

Authors:  Hirokazu Tamamura; Nobutaka Fujii
Journal:  Expert Opin Ther Targets       Date:  2005-12       Impact factor: 6.902

4.  Binding of human immunodeficiency virus type 1 gp120 to CXCR4 induces mitochondrial transmembrane depolarization and cytochrome c-mediated apoptosis independently of Fas signaling.

Authors:  R Roggero; V Robert-Hebmann; S Harrington; J Roland; L Vergne; S Jaleco; C Devaux; M Biard-Piechaczyk
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.

Authors:  P Matthys; S Hatse; K Vermeire; A Wuyts; G Bridger; G W Henson; E De Clercq; A Billiau; D Schols
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

Review 6.  Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.

Authors:  Hirokazu Tamamura; Hiroshi Tsutsumi; Hiroyuki Masuno; Nobutaka Fujii
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

7.  Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3: blockade using a monoclonal antibody in vivo.

Authors:  I Sabroe; D M Conroy; N P Gerard; Y Li; P D Collins; T W Post; P J Jose; T J Williams; C J Gerard; P D Ponath
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

8.  Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

Authors:  Zhongxing Liang; Tao Wu; Hong Lou; Xiwen Yu; Russell S Taichman; Stephen K Lau; Shuming Nie; Jay Umbreit; Hyunsuk Shim
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

9.  CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.

Authors:  Zhongxing Liang; Joann Brooks; Margaret Willard; Ke Liang; Younghyoun Yoon; Seunghee Kang; Hyunsuk Shim
Journal:  Biochem Biophys Res Commun       Date:  2007-06-04       Impact factor: 3.575

10.  Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors.

Authors:  Suazette Reid Mooring; Jin Liu; Zhongxing Liang; Jeffrey Ahn; Samuel Hong; Younghyoun Yoon; James P Snyder; Hyunsuk Shim
Journal:  ChemMedChem       Date:  2013-03-06       Impact factor: 3.466

View more
  1 in total

1.  Symmetrical bis-tertiary amines as novel CXCR4 inhibitors.

Authors:  Renren Bai; Zhongxing Liang; Younghyoun Yoon; Shuangping Liu; Theresa Gaines; Yoonhyeun Oum; Qi Shi; Suazette Reid Mooring; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2016-04-19       Impact factor: 6.514

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.